Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.83 |
| ▸ | PGR | P06401 | 16/20 | 0.83 |
| ▸ | AR | P10275 | 13/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20048408 | 0.92 | NR3C1 (0.81) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL19042673 | 0.91 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL19042656 | 0.90 | NR3C1 (0.68) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL21729781 | 0.90 | NR3C1 (0.68) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL19042680 | 0.89 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL20048209 | 0.88 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL9019810 | 0.88 | PGR (0.65) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL9019798 | 0.88 | NR3C1 (0.67) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL9019833 | 0.87 | PGR (0.64) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL21729697 | 0.86 | NR3C1 (0.64) | NR3C1PGRARCYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0404283-B1 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AG (DE) | 1996-05-08 | — | — | EP | claimed |
| JP-3128323-A | — | — | None | — | — | JP | disclosed |
| US-11208432-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210002324-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2017112909-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| JP-H03128323-A | 11BETA-ARYL-4-ESTRENE, ITS PRODUCTION, INTERMEDIATE AND PHARMACEUTICAL PREPARATION CONTAINING NEW COMPOUND AND HAVING ANTIGESTAGEN AND ANTIGLUCOCORTICOID ACTIVITIES | SCHERING AG | 1991-05-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208432-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 61/4885AR 13/4885 |
| US-20210002324-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 61/4885AR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.